Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries
For more information please visit:
Virtual Drop In:
Friday, October 16, 2020
Access the virtual drop in